Pay in 4 interest-free payments of $6.37 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
Compound Profile Scientific & Efficacy Data C 194 H 312 N 54 O 59 S 2 Molecular Formula 4409 g/mol Molecular Weight 159-195 hours (~7-8 days) Half-Life ~100% (subcutaneous) Bioavailability 1415456-99-3 CAS # 171397054 PubChem ID Developed By 2021 Thomas Kruse Novo Nordisk Primary Benefits Exceptional appetite suppression through dual amylin and calcitonin receptor activation, creating powerful and sustained satiety signals Impressive 10-15% weight loss alone, or 20%+ when combined with semaglutide in the CagriSema combination Uniquely designed to complement GLP-1 medications through an independent mechanism, dramatically enhancing results when combined Amino Acid Sequence Lys-Cys-Asn-Thr-Ala-Thr-Cys-Ala-Thr-Gln-Arg-Leu-Ala-Asn-Phe-Leu-Val-Arg-Ser-Ser-Asn-Asn-Leu-Gly-Pro-Val-Leu-Pro-Pro-Thr-Asn-Val-Gly-Ser-Asn-Thr-Tyr-NH2 (acylated with C18 diacid via gamma-Glu linker) Dosing How much do I take
GLP-1 receptor agonists downregulate aberrant GnT-III expression in Alzheimers disease models through the Akt/GSK-3/-catenin signaling
Creatine supplementation Creatine is one of the most researched and effective supplements for muscle preservation and performance
Understanding why it happens can help you take steps to minimize it
Tirzepatide activates both GLP-1 and GIP receptors, engaging broader appetite-regulation pathways than semaglutide alone
However, the anti-inflammatory effects of the metabolites may not be superior to those of resveratrol, thus reinforcing the need to improve the bioavailability of the polyphenols themselves
